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Abstract 
Background: Psoroptic mange is an important disease in Belgian Blue cattle. Treatment failure of macrocyclic lac-
tones against Psoroptes ovis has been reported, but clear evidence of in vivo resistance is lacking. This study assessed 
the efficacy of macrocyclic lactone products on 16 beef farms in Belgium and the Netherlands in vivo and in vitro.
Methods: On each farm a group of animals (n = 7–14) with psoroptic mange was treated with two subcutaneous 
injections of a macrocyclic lactone product with 7–10 days interval (15 farms) or a single injection with a long-acting 
macrocyclic lactone (1 farm). In vivo efficacy was assessed by the reduction in mite counts, clinical index (proportion 
of the body surface affected by lesions), the proportion of the animals with negative mite counts after the first treat-
ment round and the number of treatment rounds needed to obtain zero mites counts in all animals. A mite popula-
tion was categorized as sensitive when the mite count reduction after the first treatment round > 95% and the lower 
limit of the uncertainty interval > 90%. Resistance was detected when both parameters were below their threshold 
and suspected when one parameter was too low. In vitro knockdown and mortality were evaluated in a contact test.
Results: The proportion of the animals with negative mite counts after the first treatment round varied from 0 to 
80%. All farms needed two or more treatments rounds to obtain zero mite counts on all animals. Clinical index only 
started to reduce after the second treatment round. Mite populations from three farms were categorized as sensitive, 
one as suspected resistant and 12 as resistant. No correlation was found between in vitro lethal dose 50 and knock-
down dose 50 values and in vivo efficacy parameters.
Conclusions: Unambiguous treatment failure was detected on 12 out of 16 farms, confirming the presence of mac-
rocyclic lactone resistance on Belgian Blue beef farms. In vitro parameters could not discriminate the farms based on 
their in vivo sensitivity. The mean reduction in mite counts and the lower limit of the confidence interval are proposed 
as parameters to identify acaricide resistance.
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Background
Psoroptic mange is a major skin problem in sheep and 
cattle. In cattle, psoroptic mange is predominantly seen 
in the Belgian Blue breed, due to their high susceptibil-
ity to Psoroptes ovis [1]. Psoroptes ovis infestation causes 
an exudative perivascular dermatitis with intense pruri-
tus and formation of crusts. The predilection site is from 
the withers to the tail base. Excessive scratching causes 
lesions which have a higher chance of secondary bacte-
rial infection. In extreme cases, the lesions can generalize 
and result in the death of the animal [1–4]. Diminished 
animal welfare and financial losses are seen on farms with 
P. ovis problems [5, 6].
Registered treatments in Europe are limited to topical 
acaricides, such as amitraz or synthetic pyrethroids, and 
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parenteral administration of macrocyclic lactones (ML). 
Topical application of ML products is not recommended, 
due to contradictory publications about their efficiency 
to completely eliminate P. ovis [7]. In practice, it is rec-
ommended to apply acaricides twice with a 7–10-day 
interval, probably due to a lack of full ovicidal efficacy [7, 
8]. Long-acting (LA) ML products only need one appli-
cation, because of their long persistent activity [8–12]. 
Additional measures are crucial to get the desired treat-
ment result. The hair needs to be sheared and crusts need 
to be removed prior to treatment. Treatment should be 
applied to all in-contact animals and not only the clini-
cally infested animals [3, 7, 11, 12].
Treatment failure with ML products in cattle has been 
reported by Lekimme et al. [13], Mitchell et al. [14] and Sarre 
et  al. [3]. Potential reasons for treatment failure are non-
compliance with the recommended ‘good practice’ treat-
ment and acaricide resistance. Suboptimal treatment cannot 
be ruled out in the studies mentioned above, as either a long 
treatment interval (14 days) was used [13] or not all animals 
were treated in every treatment round [3]. Sarre et al. [15] 
mentioned that less than half of the Belgian farmers applied 
correct treatment against Psoroptes. Commonly made mis-
takes include underdosing, a single treatment, a long treat-
ment interval, the use of a suboptimal drug formulation or 
a lack of additional control measures, e.g. failing to shear 
the animals or partial treatment of the herd [15]. Recently, 
decreased in vitro sensitivity to ML products was seen in 
mites collected from sheep farms with reported treatment 
failure [16, 17]. Lifschitz et al. [18] reported treatment fail-
ure in cattle, despite repeated subcutaneous injection of two 
commercial formulations of ivermectin (1%) at 0.2  mg/kg 
with a short treatment interval (1 week).
Despite numerous field observations and a few published 
reports of treatment failure against P. ovis in cattle, the pres-
ence of resistant mites was not confirmed [3, 13, 18]. The 
objectives of this study were (i) to investigate the presence 
of ML resistance in beef cattle in Belgium and The Nether-
lands using different in vivo parameters; and (ii) to evaluate 
an in vitro test based on the method of Brimer et al. [19] as a 
potential diagnostic tool for ML resistance in P. ovis.
Methods
Animal selection
Sixteen Belgian Blue beef farms with psoroptic mange 
were visited during the housing period during the winters 
of 2016–2017, 2017–2018 and 2018–2019. Skin scrapings 
were collected from two to five animals per farm to con-
firm active P. ovis infestations.
A group of 7 to 13 animals was selected on each farm. 
Male or female cattle older than 4 months were used. The 
experimental group was separated from the rest of the 
herd and animals in adjacent pens were treated with an 
acaricide (injectable ML product or topical treatment with 
amitraz, twice with one-week interval) for the duration of 
the study, to preclude re-infestation of the study animals.
Animal treatment
All animals were treated with a commercially available 
injectable ML product, i.e. ivermectin  (Ivomec®, Merial, 
Toulouse, France), doramectin  (Dectomax®, Zoetis Belgium 
SA, Louvain-la-Neuve, Belgium) or moxidectin  (Cydectin®, 
Zoetis, Girona, Spain) at the recommended dose rate. On 
one farm, a long-acting formulation of moxidectin (Cydec-
tin 10%  LA®, Zoetis) was used. The animals were weighed 
on a calibrated weighing scale to determine the dose prior to 
treatment. In absence of a weighing scale, heart girth meas-
urements were used to estimate the body weight [20]. All 
animals were sheared prior to the first treatment adminis-
tration and crusts were removed as much as possible during 
shearing. Fresh bedding with or without cleaning of the sta-
ble was applied at least once per week.
A treatment round consisted of two injections with a 
7–10-day interval or a single injection with a long-act-
ing ML product, as recommended by the manufacturer. 
Treatment was evaluated 7 days after the second admin-
istration or 14 days after administration of a long-acting 
ML product. If living P. ovis were found in one or more 
animals at a given farm, a new treatment round was 
started for all the animals in the experiment.
Treatment with ML products was terminated when all 
animals had negative P. ovis mite counts, when the cat-
tle were turned out on pasture at the end of the housing 
period or if the condition of the animals warranted sal-
vage treatment. In the latter case, animals were treated 
topically with amitraz  (Taktic®, MSD Animal Health, 
Brussel, Belgium) two times with a one-week interval at 
the recommended dose.
In vivo efficacy
The clinical index (CI) and mite counts (MC) were deter-
mined before the first treatment and after every treat-
ment round. The CI is the proportion of the total body 
surface with clinical lesions. A CI was assigned to all ani-
mals by recording the skin lesions (on both sides of the 
animal) on a silhouette [21].
Skin scrapings from three different locations at the 
edge of the lesions (9  cm2/sampling location) were col-
lected in one tube per animal for MC. If sampling threat-
ened to influence the treatment results (in case of very 
small lesions), samples were taken from the predilection 
sites (withers, back, tail basis). Samples were stored at 
10 °C and analysed within 24 h after collection to identify 
and count living P. ovis mites using a stereoscopic micro-
scope (magnification 100×). If the mites were too numer-
ous to count, the sample was weighed, 1 g was taken and 
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mites were counted as previously described. Mite num-
bers were then recalculated to the total mite count of the 
pooled sample.
In vitro sensitivity
An in vitro test was based on Brimer et  al. [19]. Sterile 
polystyrene Petri dishes with an internal diameter of 92 
where MCB and MCA is the mean MC value of a num-
ber of cows before and after the first treatment round, 
respectively, with its variance approximated by the delta 
method as
Assuming that 100-RedMC follows a gamma distribution 
with shape parameter γ and scale parameter θ given by
the lower limit (LL) and upper limit (UL) of the 95% con-
fidence interval correspond to the 2.5th and the 97.5th 
quantile of the gamma distribution with shape parameter 
γ and scale parameter θ.
The RedMC and its LL and UL where then calculated 
for each farm. Calculations were done with the Paradrug 
 tool® (www.starw orms.org/tools ). Mite isolates of a 
farm were then categorized according to the methodol-
ogy used for the faecal egg count reduction test in gas-
trointestinal nematodes, with the highest sensitivity [22]. 
The mite population on a farm was considered sensitive 
when RedMC ≥ 95% and LL ≥ 90%, suspected of resist-
ance when RedMC < 95% or LL < 90% and resistant when 
RedMC < 95% and LL < 90%.
The proportion of the animals with negative mite 
counts was the fraction that was successfully treated 
(MC = 0) after the first treatment round.
In vitro sensitivity
The lethal dose 50  (LD50) values for each farm popula-
tion was calculated for the survival at 24 h and 120 h and 
knockdown dose 50  (KD50) values at 24 h using a mixed 
logistic regression model with mortality and knockdown 
as binary response variable, drug concentration as con-
tinuous independent variable and farm as random effect.
Spearmanʼs rank correlations were calculated between 
nTR, RedMC, RedCI, mite free proportion and log(LD50). 
Regression analysis was done by fitting a linear model 
with nTR, mean  RedMC, mean  RedCI or the proportion 
of the animals with negative mite counts as independent 
variable and log(LD50) as dependent variable. All calcula-
tions were done in R (version 3.5.1.) [23].



















































mm were filled with 20  ml sterile agar solution (Bidest 
with 42 g/litre Columbia agar, Sigma-Aldrich, St. Louis, 
USA) containing 1 ml horse serum (food source) and 0, 
1, 10, 100, 1000, 2000 and 5000  µg/ml ivermectin (1% 
 Ivomec®, Boehringer-Ingelheim).
The in vitro sensitivity was determined on mites from 
pooled skin scrapings from each farm. Ten mites (adults 
and nymphs from Farms 1–10, adult mites form Farms 
11–16) from each pooled sample were transferred to the 
centre of the Petri dish. The plates were kept at room 
temperature for 24 h. The mites were inspected under a 
stereomicroscope at 0, 2, 4, 6, 8 and 24 h of incubation. 
Immobility of mites and a lack of reactions or persistent 
immobility within 1  min following stimulation with a 
needle were considered indications of death. All concen-
trations were tested in triplicate, except for Farms 1 and 
8. The test for Farm 1 was conducted in duplo and with-
out the 5000 µg/ml ivermectin plates. This concentration 
was added afterwards for the other farms, as 50% mortal-
ity was not achieved with lower concentrations on Farm 
1. Farm 8 was tested in duplo, due to a shortage of mites.
Additional time points and an extra parameter (‘knock-
down’) were monitored for Farms 11–16. The status of 
the mites was recorded at 0, 5  min, 0.5, 1, 2, 4,6, 8, 24, 
48, 72 and 120 h of incubation. Knockdown was defined 
as the absence of spontaneous mobility, while movement 
was still observed after stimulation with a needle.
Statistical analysis
In vivo efficacy
Multiple parameters were monitored in vivo, i.e. number 
of treatment rounds until all animals at a given farm had 
a mite count of zero (nTR), reduction in MC after first 
treatment round (RedMC), CI reduction after two treat-
ment rounds (RedCI) and the proportion of the animals 
with zero mite counts after the first treatment round.
RedMC is defined as
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Results
Participating farms
The farms were located in Flanders, northern Belgium, 
(n = 13) and the Zeeland province of The Netherlands, 
bordering Belgium (n = 3). Group sizes varied from 7 to 
13 animals/farm. The injectable ML products used were 
ivermectin  (Ivomec®1%, n = 5), doramectin  (Dectomax®, 
n = 11), moxidectin  (Cydectin® 1 %, n = 1) and moxidec-
tin long-acting (Cydectin 10%  LA®, n = 1). One farmer 
switched from ivermectin to doramectin after the third 
injection. Moxidectin long-acting was only used on one 
farm during the first treatment round. Afterwards, the 
farmer used doramectin.
In vivo efficacy
All farms needed at least two treatment rounds and one 
farm even up to 6 rounds, to count zero mites in all ani-
mals at a given farm. The proportion of the animals with 
negative mite counts after the first treatment round var-
ied between 0–80%. The individual mite counts per ani-
mal are shown in Fig. 1.
RedMC varied from − 82.5% to 99.3% (Table  1). The 
RedMC and the corresponding uncertainty interval of 
the mite populations on all the given farms are illustrated 
in Fig.  2. Treatment with ML products was terminated 
on four farms before all animals of those farms had a 
mite count of zero, due to unsatisfying treatment results 
(Farms 2, 4 and 5) or the end of the housing period 
approached (Farm 1). These groups were successfully 
treated with amitraz (results not shown).
The evolution of the CI of the animals on the different 
farms is depicted in Fig. 3. The mean CI before treatment 
varied between 1–14%. On most farms, the skin lesions 
were completely healed (CI = 0) at the end of the treat-
ments. Farms 1, 4 and 10 had a mean CI of 1% at the end 
of the treatment. Only Farm 5 did not show any overall 
improvement of the CI during treatment.
In vitro sensitivity
The  LD50 values at 24 h in mite populations from Farm 
1 to 16 varied from 2951  µg/ml to 94,499  µg/ml with 
some populations not even reaching 50% mortality. The 
additional time point of 120 h for Farm 11 to 16 provided 
 LD50 values from 0.3 µg/ml to 58.3 µg/ml (Table 2).
KD50 were determined for Farm 11 to 16 and varied 
from 0.05 to 0.77 µg/ml ivermectin at 24 h. Neither LD 
nor KD allowed for a clear discrimination of the mite 
populations of the cattle of the 16 farms.
The regression analysis showed no correlation between 
in vivo parameters and in vitro  LD50 values. Spearmanʼs 
rank correlations were low (− 0.28–0.36) and P-values 
were too high (0.338–0.730).
Discussion
When ML products were introduced in the market, 
injectable ML products were highly effective against P. 
ovis. A single administration of the recommended (com-
mercialised) dose of an injectable ML product was suf-
ficient to kill the mites and obtain clinical cure [24–28]. 
In practice, a second injection is recommended to get the 
desired efficacy [7, 25].
In the present study, two or more treatments with 
weekly intervals were insufficient to eliminate P. ovis. 
Treatment failure of ML products against P. ovis has been 
reported in sheep and cattle [3, 13, 16, 18]. Although 
treatment failure can often be attributed to non-compli-
ance with recommended treatment and control measures 
[15], resistance of P. ovis populations against ML is sus-
pected as a cause of treatment failure [16–18] and could 
be the result of decades of frequent and indiscriminate 
use of ML.
In this study, confounding factors that could interfere 
with the detection of ML resistance were eliminated as 
much as possible. On all farms, the experimental ani-
mals were treated according to ‘good practice’, includ-
ing weighing/girth measurements to determine the dose 
rate, use of an injectable formulation and treatment of 
the whole group with appropriate treatment interval. 
Prior to treatment, crusts were removed manually and 
the animals were sheared, to optimise treatment efficacy. 
Despite these efforts, poor (or no) mite count reductions 
were obtained after the first treatment round and multi-
ple treatment rounds were needed to eliminate the mites 
and to obtain healing of the skin.
Although ML concentrations in the skin were not 
determined, it seems unlikely that treatment failure was 
due to low ML concentration in the skin of the treated 
animals, given the high number of treatments with short 
time intervals. Lifschitz et al. [18] showed high skin levels 
of ivermectin in cattle after two injections with a seven-
day interval. Although BB cattle are more susceptible to 
psoroptic mange than other breeds, ML concentrations 
in the plasma and skin of BB were actually higher than 
in Holstein-Friesian animals [29]. Based on the above, the 
observed treatment failure in the present study is highly 
indicative for ML resistance.
The reduction in MC after the first treatment round 
appeared to be the best parameter to discriminate 
between sensitive and resistant mite populations, as 
MC reductions directly measure the effect of the ML 
on the population of mites. The number of treatment 
rounds and the proportion of the animals with nega-
tive mite counts after the first treatment round did not 
discriminate between populations, although they are 
derived from the reduction in MC. CI failed to differen-
tiate between populations after treatment, since clinical 
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Fig. 1 The individual mite counts of each animal (sum of the three pooled samples) are depicted for the 16 farms. MC are given on the y-axis 
and time in number of treatment rounds on the x-axis. t0 refers to the count prior to the initiation of the first treatment round, t1 is after the first 
treatment round, etc. Each line depicts MC values of one animal over time
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recovery requires more time than mite eradication. This 
is also observed in ML sensitive mites [12].
To date, no threshold for mite count reductions has 
been defined to distinguish sensitive from resistant mite 
populations in vivo. We have based our classification of 
resistance on the methodology with highest sensitivity 
to detect anthelmintic resistance in ruminant nematodes 
using a faecal egg count reduction test [22, 30]. Using 
the LL of the UI and the RedMC described by Coles 
et al. [30], we identified three farms with sensitive mites, 
one farm was classified as ‘suspected resistance’ and 12 
farms had resistant mite populations. This methodology 
was used because of the lack of resistance guidelines for 
ectoparasites in cattle. The World Association for the 
Advancement of Veterinary Parasitology (WAAVP) and 
the European Medicines Agency do have guidelines for 
the efficacy of new acaricides, recommending MC as effi-
cacy parameter and a 90% mean reduction in MC after 
treatment as sufficient [31, 32]. Compared with these 
guidelines for acaricide efficacy, the thresholds we used 
to distinguish sensitive from resistant mite isolates may 
seem to be harsh. However, survival of 10% of the mites 
could quickly result in a relapse of psoroptic mange in 
the treated animals, as the mite population can double 
in size every six days under favourable conditions [33]. 
Moreover, even if the WAAVP efficacy guidelines for 
acaricide efficacy would have been followed, ML effi-
cacy would only be sufficient on 5 out of 16 farms (MC 
reduction > 90%), which supports our conclusion that ML 
resistance is widespread in BB farms in northern Belgium 
and the south of the Netherlands. The presence of ML 
resistance in Belgium is no surprise, since compliance 
with the recommended treatment is poor in the majority 
of Belgian beef farmers [15]. The emergence of ML resist-
ance in P. ovis in beef farms in different countries (Argen-
tina, Belgium, the Netherlands) is concerning and needs 
further investigation. Beef farmers should be instructed 
about good practices in mange control to slow down fur-
ther spreading and development of resistance. Research 
is ongoing to identify the factors that may impede or 
facilitate adoption of these practices among farmers [34].
An in vitro test based on exposure of mites to different 
concentrations of acaricides on agar plates [19] has been 
used to differentiate sensitive and resistant mites [16]. An 
Table 1 In vivo efficacy of macrocyclic lactone products against Psoroptes ovis on 16 Belgian Blue beef farms in Belgium and the 
Netherlands
Abbreviations: CI, confidence interval; IVM, ivermectin injectable (Ivomec 1%®); DOR, doramectin injectable  (Dectomax®); MOX, moxidectin injectable  (Cydectin®); LA, 
moxidectin injectable long-acting formulation; RedMC, average reduction in mite counts on a given farm after the first treatment round; nTR, number of treatment 
rounds until all animals at a given farm had a mite count of zero; mite-free proportion, the proportion of the animals with negative mite counts after the first 
treatment round
Farm No. of animals Acaricide RedMC (%) 95% CI Resistance status nTR Mite-free 
proportion 
(%)
1 13 IVM 68.5 25.4–93.2 Resistant > 7 0/13 (0)
2 10 IVM 99.3 97.7–100 Sensitive 4 8/10 (80)
3 9 IVM /DOR 33.3 − 65.8 to 87.6 Resistant 3 2/9 (22)
4 7 MOX-LA DOR 7.6 − 58.6 to 56.1 Resistant > 4 0/7 (0)
5 9 IVM − 36.8 − 200.7 to 63.0 Resistant > 5 0/7 (0)
6 9 DOR 97.8 92.4–99.0 Sensitive 2 4/9 (44)
7 9 DOR 78.5 72.2–83.9 Resistant 4 2/9 (22)
8 9 IVM -82.5 − 203.1 to 7.8 Resistant 5 2/9 (22)
9 10 DOR 97.8 94.0–99.7 Sensitive 3 5/10 (50)
10 9 MOX 89.7 65.4–99.5 Resistant 4 2/9 (22)
11 9 DOR 80.4 56.7–94.8 Resistant 2 3/9 (33)
12 9 DOR 95.8 86.2–99.8 Suspected resistant 4 1/9 (11)
13 8 DOR 50.3 29.7–67.8 Resistant 3 4/8 (50)
14 8 DOR 86.2 77.8–92.7 Resistant 3 5/8 (63)
15 10 DOR 65.5 51.6–77.0 Resistant 2 2/10 (20)
16 9 DOR 92.0 82.6–97.8 Resistant 3 3/9 (33)
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in vitro test would be useful to determine the resistance 
status of mite populations without the need to perform a 
labour-intensive mite count reduction test. However, in 
our hands, the in vitro test failed to distinguish the mite 
populations with different in vivo sensitivity from each 
other and in vitro test results did not correlate with in 
vivo efficacy. Despite large differences in MC reductions 
and CI reductions between farms, the in vitro efficacy 
showed a similar pattern in all farms and  LD50 values or 
 KD50 values did not vary with in vivo efficacy. The rea-
son for this is unknown. To our knowledge, data about 
the reproducibility between laboratories are not available 
[19, 22].
Conclusions
Unambiguous treatment failure of ML products was 
detected on 12 out of 16 beef farms, confirming the pres-
ence of ML resistance in Belgian Blue beef farms in Bel-
gium and the Netherlands. Tentative in vitro parameters 
could not detect ML resistance. The reduction in mite 
counts after the first treatment round (two administra-
tions of an injectable ML product) appears to be a suit-
able parameter to monitor acaricide resistance. A mean 
reduction in mite counts of < 95% combined with a lower 
limit of the 95% uncertainty interval < 90% are proposed 
as criteria for the detection of resistance against ML in 
P. ovis.
Fig. 2 RedMC is depicted for the mite populations of the given farms. The uncertainty intervals are given by the whiskers. The 90% and 95% 
threshold are indicated by red lines
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Abbreviations
ML: macrocyclic lactones; LA: long-acting; CI: clinical index; MC: mite counts; 
nTR: number of treatment rounds; RedMC: reduction in mite counts; RedCI: 
reduction in clinical index; MCB: mite counts before the first treatment round; 
MCA: mite counts after the first treatment round; LL: lower limit of the confi-
dence interval; LD50: lethal dose 50; KD50: knockdown dose 50; IVM: ivermectin; 
DOR: doramectin; MOX: moxidectin.
Acknowledgments
We would like to thank all the farmers and veterinarians for their participation.
Authors’ contributions
WVM participated in the design of the study, manuscript writing, data analysis 
and performed the experiments. NDW, SC and MV participated in the in vivo 
efficacy studies. ZC assisted with the in vitro assays. LD performed the statisti-
cal analysis and contributed to the writing of the manuscript. EC designed 
the study and participated in the manuscript writing. All authors read and 
approved the final manuscript.
Funding
This study was funded by a Special Research Fund-Interdisciplinary Research 
Project (BOF-IOP) from Ghent University (Grant code BOF.24J.2016.0004.01).
Availability of data and materials
Data supporting the conclusions of this article are included within the article. 
The datasets used and/or analysed during the present study are available from 
the corresponding author upon reasonable request.
Ethics approval and consent to participate
Ethical approval to conduct this study was obtained from the Ethical Com-
mittee of the Faculties of Veterinary Medicine and Bio-engineering Sciences, 
Ghent University (Ethical approval number EC2016/42). All participating farm-




The authors declare that they have no competing interests.
Author details
1 Laboratory of Parasitology, Faculty of Veterinary Medicine, Ghent University, 
Salisburylaan 133, 9820 Merelbeke, Belgium. 2 Biometrics Research Center, Fac-
ulty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merel-
beke, Belgium. 
Received: 11 December 2019   Accepted: 6 March 2020
Fig. 3 The progress of the clinical index for the animals on each farm. t0 refers to the clinical index prior to the first treatment round, t1 is the clinical 
index after the first treatment round, t2 is the clinical index after the second treatment round … t6 is the clinical index after the sixth treatment 
round
Table 2 LD50 at 24 h and at 120 h and  KD50 at 24 h for 
ivermectin in P. ovis populations from 16 Belgian Blue farms in 
Belgium and the Netherlands
Abbreviation: na, data not available
Farm LD50; 24 h (µl/ml) LD50; 120 h (µl/ml) KD50; 24 h (µl/ml)
1 36867 na na
2 2951 na na
3 2992 na na
4 3972 na na
5 3417 na na
6 3430 na na
7 4172 na na
8 3121 na na
9 3175 na na
10 3304 na na
11 6.538 × 106 23.1 0.19
12 11.337 2.7 0.08
13 3191 0.3 0.18
14 7429 58.3 0.05
15 6857 10.4 0.33
16 94499 3.6 0.77
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